■在中国国家癌症中心(NCC)治疗的不同阶段胃癌患者的术后生存率尚未见报道。因此,我们评估了2011-2018年在NCC接受手术的胃癌患者的生存率,为进一步研究提供基线信息.
■我们确定了2011年1月至2018年5月期间在NCC接受手术的7301例原发性胃癌患者;其中,5,008名患者参加了这项研究。后续工作已于2020年4月30日完成。我们根据阶段分析了5年生存率,性别,年龄,和其他临床病理特征。
■pTNM分期IA患者的5年生存率,IB,IIA,IIB,IIIA,IIIB,IIIC,在NCC治疗的IV为94.9%,91.8%,86.5%,76.1%,61.1%,44.2%,29.7%,和8.1%,分别,这与同期日本报告的情况相似。ypTNMⅠ期患者的5年生存率,II,III,IV为93.1%,63.2%,27.2%,和0.0%,分别。在多变量分析中,年龄,印戒细胞癌,辅助化疗,分化程度是重要的预后因素。
■在NCC治疗的胃癌患者的生存率得到了显著提高,在同一时期达到日本的水平。
UNASSIGNED: The postoperative survival rates of patients with gastric cancer at different stages treated at the National Cancer Center (NCC) of China have not been reported. Therefore, we evaluated the survival of patients with gastric cancer who underwent surgery at the NCC from 2011 to 2018 to provide baseline information for further studies.
UNASSIGNED: We identified 7,301 patients with primary gastric carcinoma who underwent surgery at the NCC between January 2011 and May 2018; among these, 5,008 patients were enrolled in this study. Follow up was completed on April 30, 2020. We analyzed the 5-year survival according to the stage, sex, age, and other clinicopathological features.
UNASSIGNED: Five-year survival rates of patients with pTNM stages IA, IB, IIA, IIB, IIIA, IIIB, IIIC, and IV treated at the NCC were 94.9%, 91.8%, 86.5%, 76.1%, 61.1%, 44.2%, 29.7%, and 8.1%, respectively, which were similar to those reported in Japan during the same period. Five-year survival rates of patients with ypTNM stages I, II, III, and IV were 93.1%, 63.2%, 27.2%, and 0.0%, respectively. In multivariable analysis, age, signet ring cell carcinoma, adjuvant chemotherapy, and degree of differentiation were revealed as important prognostic factors.
UNASSIGNED: The survival rates of patients with gastric cancer treated at the NCC have been significantly improved, reaching the levels of Japan in the same period.